myLaminin Perspectives

earn how sponsors can manage protocol deviations, amendments, eTMF documentation, and regulatory compliance in multi-site clinical trials under evolving ICH E6(R3) expectations.

Multi-site clinical trials are widely used across North America to improve recruitment and accelerate timelines, but hidden operational risks often undermine success. Site variability, uneven engagement, communication breakdowns, and fragmented technology adoption create systemic inefficiencies that erode data quality and compliance. Without integrated oversight and standardized processes, complexity scales faster than control, increasing trial failure risk.

Poor clinical trial coordination drives costly delays, data integrity risks, and regulatory exposure across multi-site studies in Canada, the US, and globally. Fragmented systems, inconsistent documentation, and weak communication slow approvals, inflate Phase III costs, and erode patient trust. Integrated CTMS/CR/os platforms like myLaminin unify stakeholders, streamline workflows, strengthen compliance, and enable real-time oversight turning coordination into a competitive

Running clinical trials without a Clinical Trial Management System (CTMS) creates hidden operational burdens, from fragmented data and compliance risks to poor collaboration and reduced patient engagement. Disconnected tools like spreadsheets and email slow execution, increase errors, and threaten data integrity. A centralized CTMS streamlines workflows, ensures regulatory compliance, and improves trial efficiency, making it essential for scalable, secure, and successful clin